Role Definition
| Field | Value |
|---|---|
| Job Title | Parasitologist (BLS SOC 19-1099 Life Scientists, All Other / 19-1022 Microbiologists) |
| Seniority Level | Mid-Level (3-8 years post-PhD, independent research capability) |
| Primary Function | Studies parasitic organisms (helminths, protozoa, ectoparasites) and parasitic diseases affecting humans and animals. Conducts fieldwork in endemic regions collecting specimens, performs laboratory analysis (microscopy, molecular diagnostics, culture), designs drug/vaccine efficacy studies, and contributes to public health surveillance and control programmes. Typically based at research institutions (e.g. Liverpool School of Tropical Medicine, CDC, WHO), universities, or pharmaceutical companies. |
| What This Role Is NOT | Not a microbiologist (SOC 19-1022 — broader microbial focus, scored 49.8 Green). Not a medical scientist (SOC 19-1042 — clinical trial focus, scored 54.5 Green). Not a biological technician (executes protocols under supervision, scored 28.2 Yellow). Not an epidemiologist (population-level disease patterns, scored 48.6 Green). |
| Typical Experience | PhD in parasitology, tropical medicine, or related life science (4-6 years graduate training). 2-5 years post-doctoral research. May hold DTM&H (Diploma in Tropical Medicine and Hygiene). |
Seniority note: Junior (postdoc, 0-2 years independent) would score lower Green (~48-50) — less fieldwork autonomy, more protocol execution. Senior PIs and programme directors would score higher Green (~58-62) due to strategic research direction, grant accountability, and institutional leadership.
Protective Principles + AI Growth Correlation
| Principle | Score (0-3) | Rationale |
|---|---|---|
| Embodied Physicality | 2 | Fieldwork in endemic tropical regions — collecting blood, stool, and tissue samples from human and animal hosts in remote, unstructured environments (villages, forests, water bodies). BSL-2/BSL-3 lab work with dangerous pathogens. This is not structured factory-floor physicality; it is unpredictable field science in low-resource settings. |
| Deep Interpersonal Connection | 1 | Collaborates with local health workers, community leaders, and patients in endemic regions. Mentors junior researchers. Builds cross-institutional partnerships. Professional relationships matter but trust is not the sole value delivered. |
| Goal-Setting & Moral Judgment | 3 | Defines novel research questions about parasite biology, host-parasite interactions, drug resistance mechanisms, and transmission dynamics. Makes ethical decisions about human subjects research in vulnerable populations. Frontier parasitology — investigating new drug targets, characterising emerging resistance — requires genuine novelty with no playbook. |
| Protective Total | 6/9 | |
| AI Growth Correlation | 0 | AI adoption neither creates nor destroys demand for parasitologists. Demand driven by neglected tropical diseases (WHO NTD roadmap), antimicrobial/antiparasitic resistance, climate-driven range expansion of vectors, and fundamental biological questions about host-parasite co-evolution. |
Quick screen result: Protective 6/9 with strong physicality and goal-setting. Likely Green Zone — proceed to confirm.
Task Decomposition (Agentic AI Scoring)
| Task | Time % | Score (1-5) | Weighted | Aug/Disp | Rationale |
|---|---|---|---|---|---|
| Hypothesis generation & experimental design | 20% | 2 | 0.40 | AUG | AI synthesises literature and suggests research gaps. But generating novel hypotheses about parasite immune evasion, drug resistance mechanisms, or host-parasite co-evolution requires deep domain intuition and creative leaps. Scientist defines what to investigate. |
| Fieldwork & sample collection (endemic regions) | 15% | 1 | 0.15 | NOT | Collecting specimens from humans/animals in remote tropical settings — blood draws in village clinics, snail sampling from water bodies, vector trapping in forests. Unstructured, unpredictable physical environments. No robotic alternative. Requires cultural sensitivity with local communities. |
| Laboratory research (microscopy, culture, molecular diagnostics) | 20% | 2 | 0.40 | AUG | Wet lab — parasite identification by microscopy, in vitro culture of Plasmodium/Leishmania/helminths, PCR/qPCR, drug sensitivity assays. AI-powered microscopy assists species identification but complex morphological interpretation, culture troubleshooting, and novel assay development remain human-led. |
| Data analysis & bioinformatics | 15% | 3 | 0.45 | AUG | AI handles significant sub-workflows: genomic/transcriptomic analysis of parasites, phylogenetic modelling, drug target prediction, epidemiological modelling of transmission. Scientist leads interpretation, validates biological significance, designs follow-up experiments. |
| Scientific writing, reporting & publication | 10% | 3 | 0.30 | AUG | AI drafts sections, manages references, generates figures. Framing discoveries for WHO policy recommendations, peer review, or drug development milestones requires deep scientific and public health expertise. |
| Quality control, compliance & regulatory | 10% | 2 | 0.20 | AUG | GLP/GCP compliance for drug efficacy trials, ethics committee submissions for human subjects research, biosafety protocols for pathogen handling. Human accountability for regulatory compliance is non-negotiable. |
| Supervision, mentoring & collaboration | 5% | 1 | 0.05 | NOT | Training junior parasitologists, managing field teams, coordinating with WHO/CDC/local health ministries. Human relationships and mentorship. |
| Method development & protocol optimization | 5% | 2 | 0.10 | AUG | Developing new diagnostic assays, optimising culture conditions for difficult parasites, validating AI-predicted drug candidates through phenotypic screening. |
| Total | 100% | 2.05 |
Task Resistance Score: 6.00 - 2.05 = 3.95/5.0
Displacement/Augmentation split: 0% displacement, 80% augmentation, 20% not involved.
Reinstatement check (Acemoglu): AI creates new tasks: validating AI-powered diagnostic outputs against gold-standard microscopy, testing AI-predicted drug targets through phenotypic assays, interpreting AI-generated phylogenomic models of parasite evolution, and curating training data for parasite identification ML models.
Evidence Score
| Dimension | Score (-2 to 2) | Evidence |
|---|---|---|
| Job Posting Trends | 1 | Parasitology diagnostics market growing at 12.8-20% CAGR (2025-2032). BLS projects 5% growth for microbiologists, 3-4% for life scientists all other. Specialist parasitology roles (tropical medicine, NTD research) show steady demand from WHO, CDC, academic institutions, and pharma. Average salary $131,823 reflects specialist premium. |
| Company Actions | 0 | No companies cutting parasitologists citing AI. Pharma investing heavily in antiparasitic drug discovery (Novartis, GSK NTD programmes). Biopharma layoffs (~42,700 in 2025) business-cycle driven, not AI displacement. WHO NTD roadmap 2021-2030 sustains institutional demand. Neutral net signal. |
| Wage Trends | 0 | Average $131,823 (specialist premium over $81,990 microbiologist median). Wages tracking inflation. Computational parasitology skills command moderate premiums but no surge. |
| AI Tool Maturity | 1 | AI microscopy for parasite species identification (malaria, helminth eggs), genomic analysis pipelines, drug target prediction tools, epidemiological modelling platforms. All augment rather than replace — require parasitologist oversight and experimental validation. No autonomous AI parasitology system exists. Anthropic data: Biological Scientists All Other 24.5% observed exposure, Medical Scientists 3.8% — low, predominantly augmented. |
| Expert Consensus | 1 | Research consensus: AI "transforming diagnostics, drug discovery, and surveillance" in parasitology but human oversight essential. Nature Reviews: neural networks classify parasite species but trained parasitologists validate. WHO and NTD community emphasise need for field expertise. No credible source predicts mid-level parasitologist displacement. |
| Total | 3 |
Barrier Assessment
Reframed question: What prevents AI execution even when programmatically possible?
| Barrier | Score (0-2) | Rationale |
|---|---|---|
| Regulatory/Licensing | 1 | PhD required by convention. FDA/EMA require qualified human investigators for drug efficacy trials. Ethics committees mandate human PIs for research involving human subjects in endemic regions. No regulatory pathway for autonomous AI-led parasitological research or public health determinations. |
| Physical Presence | 2 | Fieldwork in remote endemic regions is core to the role — collecting specimens from humans, animals, and environmental sources in unstructured tropical environments. BSL-2/BSL-3 lab work with dangerous pathogens. Cannot be performed remotely or by robots. |
| Union/Collective Bargaining | 0 | Scientists not unionised. Some government/WHO employees have civil service protections but minimal impact. |
| Liability/Accountability | 1 | Professional accountability for diagnostic accuracy in clinical parasitology, drug safety evaluations, public health recommendations, and research ethics in vulnerable populations. Incorrect species identification or drug resistance assessment can lead to treatment failure and patient harm. |
| Cultural/Ethical | 1 | Scientific community values human-driven discovery. Regulatory bodies (WHO, FDA, national health agencies) require human oversight. Fieldwork with endemic communities requires human cultural competence and trust-building. Journals require AI disclosure. |
| Total | 5/10 |
AI Growth Correlation Check
Confirmed 0 (Neutral). AI adoption does not create or destroy demand for parasitologists. Demand driven by the WHO NTD roadmap (targeting elimination of 20 diseases by 2030), antimalarial/antiparasitic drug resistance, climate-driven expansion of vector ranges into new territories, and fundamental research into host-parasite biology. AI makes researchers more productive but does not change whether human parasitologists are needed. Not Accelerated Green (no recursive AI dependency).
JobZone Composite Score (AIJRI)
| Input | Value |
|---|---|
| Task Resistance Score | 3.95/5.0 |
| Evidence Modifier | 1.0 + (3 x 0.04) = 1.12 |
| Barrier Modifier | 1.0 + (5 x 0.02) = 1.10 |
| Growth Modifier | 1.0 + (0 x 0.05) = 1.00 |
Raw: 3.95 x 1.12 x 1.10 x 1.00 = 4.8664
JobZone Score: (4.8664 - 0.54) / 7.93 x 100 = 54.6/100
Zone: GREEN (Green >= 48, Yellow 25-47, Red <25)
Sub-Label Determination
| Metric | Value |
|---|---|
| % of task time scoring 3+ | 25% |
| AI Growth Correlation | 0 |
| Sub-label | Green (Transforming) — >= 20% task time scores 3+, AIJRI >= 48 |
Assessor override: None — formula score accepted.
Assessor Commentary
Score vs Reality Check
The 54.6 AIJRI places this role firmly in Green, 6.6 points above the Green/Yellow boundary. Compare to Microbiologist (49.8) — parasitologists score higher due to stronger physical presence barrier (fieldwork in endemic regions scores 2 vs 1 for structured lab environments), slightly higher task resistance (3.95 vs 3.85) from irreducible fieldwork, and marginally stronger evidence from growing parasitology diagnostics markets. Compare to Virologist (53.8) and Immunologist (53.2) — parasitologists calibrate in the same band, consistent with life sciences researchers who combine hypothesis-driven research, physical lab/field work, and regulatory accountability.
What the Numbers Don't Capture
- Field-to-desk ratio varies dramatically. Parasitologists at LSHTM or CDC doing tropical fieldwork 30-40% of the time are far more protected than those in purely computational parasitology or bioinformatics roles. The 54.6 score reflects the typical mid-level researcher with regular field exposure.
- NTD funding as demand floor. The WHO NTD roadmap and Gates Foundation commitments create sustained institutional demand independent of AI trends. The +3 evidence score may understate this structural demand floor.
- Small occupation effect. Parasitologists are a sub-population within Life Scientists All Other (7,800 total). Small movements in institutional funding create outsized volatility in demand.
Who Should Worry (and Who Shouldn't)
Parasitologists doing fieldwork in endemic regions and designing novel experiments should not worry. If you collect specimens in tropical settings, generate hypotheses about parasite biology, and design drug/vaccine efficacy studies, you are doing work AI cannot replicate. The "Transforming" label means your data analysis, bioinformatics, and literature review workflows are changing fast — embrace AI tools and you become more productive. Most protected: those in tropical medicine fieldwork, antiparasitic drug resistance research, and clinical parasitology bearing diagnostic accountability. More exposed: parasitologists in purely computational roles (bioinformatics, modelling) without wet-lab or field components — these face the same compression as other computational scientists. The single biggest factor: whether you work with living parasites in physical settings or solely with data about them.
What This Means
The role in 2028: Parasitologists will use AI as standard research infrastructure — ML-powered microscopy for rapid species identification, genomic analysis pipelines for drug resistance profiling, AI-assisted drug target prediction, and automated literature synthesis. Fieldwork remains irreducibly human. The scientist still generates every hypothesis, designs every experiment, validates every AI prediction against culture-based and clinical reality, and bears accountability for public health recommendations.
Survival strategy:
- Develop computational skills — learn Python/R, genomic analysis pipelines, and how to critically evaluate AI-generated parasite identification and resistance predictions. The parasitologist who bridges field science and computational biology is most valuable.
- Maintain and deepen field expertise — tropical medicine fieldwork, community engagement in endemic regions, and hands-on diagnostic microscopy are the strongest moats against automation.
- Specialise in high-demand frontier areas — antiparasitic drug resistance, climate-driven disease emergence, zoonotic parasites, or diagnostic validation — where novel questions outpace AI's ability to answer them from existing data.
Timeline: 10-15+ years. Constrained by the irreducibility of fieldwork in unstructured endemic environments, working with living organisms requiring physical manipulation, regulatory mandates for human oversight in drug development and public health, and the expanding frontier of parasite biology driven by climate change and drug resistance.
